Back

LOw-dose RAbeprazole therapy for reducing gastrointestinal events in patients with High Bleeding Risk (LORA-HBR): a prospective, multicenter, interventional study

1 September 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Anticoagulation pharmacotherapy updates Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Eun Jin Park

Korea University Guro Hospital, Seoul (Korea (Republic of))

4 More presentations in this session

Presentation thumbnail
Trends and outcomes of direct oral anticoagulant use in patients with cancer: a nationwide cohort study
Doctor A. Holt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes of direct oral anticoagulants versus warfarin for chronic thromboembolic pulmonary hypertension: a reconstructed individual patient data meta-analysis
Doctor A. Chng (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Effectiveness and safety of direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis
Mr K. Chagas (Itaperuna, BR)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of direct oral anticoagulants compared to warfarin for LV thrombus resolution
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

1 September 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Safety and effectiveness of tegoprazan in patients treated with dual antiplatelet therapy after drug-eluting stent implantation for acute myocardial infarction.
thumbnail
Congress Presentation
Association between reduced risk of gastrointestinal bleeding related to proton pump inhibitor use and subsequent all-cause death in patients with percutaneous coronary intervention
thumbnail
Congress Presentation
Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources